EP Patent

EP3616695A1 — Methods for treating intrapulmonary infections

Assigned to Merck Sharp and Dohme LLC · Expires 2020-03-04 · 6y expired

What this patent protects

This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

USPTO Abstract

This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

Drugs covered by this patent

Patent Metadata

Patent number: EP3616695A1
Jurisdiction: EP
Classification: —
Expires: 2020-03-04
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.